News
PALI
5.41
-7.52%
-0.44
PALISADE BIO INC - COMPANY ON TRACK TO COMMENCE PHASE 1 HUMAN CLINICAL STUDY OF LEAD PRODUCT CANDIDATE, PALI-2108, FOR TREATMENT OF UC BEFORE YEAR END
Reuters · 16h ago
Weekly Report: what happened at PALI last week (0513-0517)?
Weekly Report · 1d ago
Buy Rating Affirmed for Palisade Bio’s PALI-2108 Amid Strong Financials and Promising Partnership
TipRanks · 4d ago
Palisade Bio GAAP EPS of -$4.59
Palisade Bio, Inc. Reports Q1 GAAP EPS of -$ . The company had cash and cash equivalents of $ million as of March 31, 2024. Palisade's net loss for the three months ended March 24, 2024 was $  million.
Seeking Alpha · 05/14 14:22
Palisade Bio Q1 EPS $(4.59) Misses $(4.28) Estimate
Benzinga · 05/14 12:36
PALISADE BIO REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Reuters · 05/14 12:05
PALISADE BIO INC - SUFFICIENT CASH ON HAND TO EXECUTE ON BUSINESS PLAN AND REACH CLINICAL AND REGULATORY MILESTONES INTO 2025
Reuters · 05/14 12:05
*Palisade Bio 1Q Loss/Shr $4.59 >PALI
Dow Jones · 05/14 12:05
*Palisade Bio 1Q Research and Development Expenses $2.2M >PALI
Dow Jones · 05/14 12:05
PALI Stock Earnings: Palisade Bio Beats EPS for Q1 2024
Palisade Bio reported earnings per share of -$ for the first quarter of 2024. The company did not report any revenue for the quarter. Palisade bio reported earnings above the analyst estimate for -$ per share. The biotech company reported results for the fourth quarter of 2016.
Investorplace · 05/14 02:53
Palisade Bio, Inc. 10-Q Financial Report
Press release · 05/14 01:53
Weekly Report: what happened at PALI last week (0506-0510)?
Weekly Report · 05/13 09:47
Palisade Bio Welcomes New Board Member, Eyes Strategic Growth
TipRanks · 05/10 21:02
PALISADE BIO INC FILES FOR RESALE OF UP TO 1.6 MLN SHARES BY THE SELLING STOCKHOLDERS - SEC FILING
Reuters · 05/08 21:07
*Palisade Bio Appoints Margery Fischbein to Its Bd of Directors
Dow Jones · 05/07 12:31
PALISADE BIO APPOINTS MARGERY FISCHBEIN TO ITS BOARD OF DIRECTORS
Reuters · 05/07 12:30
PALISADE BIO ANNOUNCES CLOSING OF $4 MILLION PRIVATE PLACEMENT PRICED AT-THE- MARKET UNDER NASDAQ RULES
Reuters · 05/07 11:30
Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
Palisade Bio, Inc. Is a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company closed its previously announced private placement with an institutional investor for gross proceeds of approximately $4 million.
Barchart · 05/07 06:30
Weekly Report: what happened at PALI last week (0429-0503)?
Weekly Report · 05/06 09:49
12 Health Care Stocks Moving In Friday's After-Market Session
NeuBase Therapeutics (NASDAQ:NBSE) stock increased by 11.1% to $0.45 during Friday's after-market session. Asensus Surgical (AMEX:ASXC) shares moved upwards by 5.43%. The company's market cap stands at $69.1 million.
Benzinga · 05/03 20:31
More
Webull provides a variety of real-time PALI stock news. You can receive the latest news about Palisade Bio Inc through multiple platforms. This information may help you make smarter investment decisions.
About PALI
Palisade Bio, Inc. is a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal diseases. It is engaged in advancing a PALI-2108 for the treatment of IBD, including UC and CD and are researching PALI-1908. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract. UC primarily affects the colon and the rectum. CD can affect any part of the gastrointestinal tract, from the mouth to the anus. PALI-2108 is a prodrug PDE4 inhibitor that operates through a mechanism within colon tissues, targeting the key enzyme phosphodiesterase-4 (PDE4). This enzyme is pivotal in cAMP hydrolysis, and by inhibiting PDE4, intracellular cAMP levels are elevated. This elevation leads to the downregulation of inflammatory cytokines and a reduction in the expression of cell adhesion molecules. By modulating these processes, PALI-2108 prevents the local infiltration and activation of inflammatory cells in the colon tissues.